Late malignancies have been discussed as a potential risk for growth factor mobilized donors of hematopoietic stem cells. Little is known about the incidence and potential risk factors. This single center retrospective cohort study evaluated all HLA-identical sibling pairs with hematopoietic stem cell transplantation (HSCT) for a hematological malignancy, treated from 1974 to 2001 at the University Hospital of Basel. Three hundred eighteen pairs were identified, 291 donors (92%) could be contacted. Median observation time was 13.8 years (range 5-32 years). Sixteen (5%) donors had developed a total of 18 tumors, 17 recipients a secondary tumor. According to the age-and sex-adapted cancer incidence, 3.3 tumors in male and 6.8 in female donors were expected, 3 (relative risk (RR): 0.91, 95% confidence interval: 0.19-2.66) and 4 (RR: 0.58, 95% confidence interval: 0.16-1.48), respectively, were found in donors between 0 and 49 years. Between 50 and 69 years, 4.5 tumors in males and 4.8 in females were expected, 5 (RR: 1.11, 95% confidence interval: 0.36-2.59) and 6 (RR: 1.23, 95% confidence interval: 0.45-2.67), respectively, were observed. Tumors do occur in donors of hematopoietic stem cells at least at the rate as expected in a normal population; whether incidence exceeds expected rates needs to be determined in larger international cohorts.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) has become the standard of care for many patients with hematological malignancies and other severe congenital or acquired disorders of the hematopoietic system. First reports on successful BM transplants from HLA-identical siblings for patients with immune deficiency disorders date from 1968. 1 Over the last decade, the number of HSCT has been steadily increasing worldwide, with acute myeloid leukemia being the most frequent indication. 2 Over time, the focus has moved from immediate recipient survival to long-term follow-up and quality of life. It has become evident that HSCT is associated with significant early and late morbidity and mortality of the recipients. 3, 4 The development of a secondary cancer is one of these concerns. 5 In addition, there has been a shift in concern for donors. For too long, risks have been considered as minimal and negligible. A need for care about potential consequences that could affect persons who donated BM and/or peripheral blood stem cells has become evident. Retrospective donor data from the EBMT showed that severe adverse events and hematologic malignancies occurred after stem cell donation. 6 Isolated reports of spleen rupture and cardiovascular complications occurring during the mobilization phase of the procedure have also been published 7 as well as reports about donors who suffered from leukemia at the time of donation. 8 Little is known about potential risk factors for occurrence of a malignancy in donors of hematopoietic stem cells. The possibility of an increased risk of acute leukemia arising as a result of mobilization with G-CSF has been discussed. 9, 10 Furthermore, donor and recipient are often members of the same family and share the same HLA alleles. An increased familial risk for hematological malignancies as well as an association of the HLA system with cancer is well known. Families with multiple individuals affected with hematological malignancies have been described in the literature. 11, 12 Information on incidence, type and risk factors for malignancies after hematopoietic stem cell donation compared with malignancies in the respective recipients and in the general population are therefore urgently warranted.
Patients and methods

Study design
Between August 1974 and December 2001, a total of 416 HLA-identical sibling pairs have been treated with an allogeneic HSCT for malignant hematological diseases at the University Hospital Basel. For logistical reasons, only donor-recipient pairs living in Switzerland or Southern Germany (n ¼ 318, 76%) were included in this single center retrospective cohort study.
Unrelated or mismatched pairs, pairs with a HSCT for a non-malignant disease and recipients referred to HSCT from abroad were excluded.
Demographics of donors and recipients were taken from the recipients' charts of the transplant unit, irrespectively of whether the recipient was dead or alive. These basic data did include donor sex, age, date of donation, age at donation, stem cell source (BM or PBSC), number of donations, relation to recipient (HLA-identical sibling or twin) and age at follow-up. Information about the recipients did include sex, age, diagnosis, date of transplantation and follow-up. Information about secondary malignancies and survival status were obtained from the annual follow-up at the University Hospital of Basel.
Donors were contacted by telephone or mail and asked about their current health status, especially the existence or history of malignancies. Subjects were followed up until January 2007. In the case of occurrence of a cancer, information about age at diagnosis, localization and histology of the tumor and treatment was obtained by contacting the donor's treating physicians. Only malignancies were included, semi-malignant (for example basalioma) and benign tumors were excluded.
Statistical analysis
The data obtained were compared with the age-and sexadapted cancer incidence of the general population. The incidence of malignancies in donors was also compared with the incidence of secondary tumors occurring in the recipients.
Tumor rates in donors were compared with the age-and sex-adapted cancer incidence rate of the Swiss Association of Cancer Registries. 13, 14 For the calculations, the Person-years program (WHO-IARC) was used. The same information was retrieved for the recipients. Cumulative incidences of tumors in recipients and donors were calculated and compared by using the Gray test, treating death from any cause as a competing risk. To account for the higher risk of dying free of a secondary tumor in the recipients' population, KaplanMeier estimates of tumor incidence were calculated and compared by log-rank test.
Results
Population description
Three hundred eighteen HLA-identical sibling donorrecipient pairs meet the inclusion criteria, 291 (92%) donors could be contacted (Table 1) . Twenty-seven donors (8%) were lost to follow-up. There were 142 men and 149 women. Fourteen were twins. Median age at donation was 32 years (range 6 months to 68 years). Median observation time was 13.8 years (range 5-32 years). At last follow-up, median age was 47 years (range 11-85 years), with 85% of the donors o60 years: 146 donors were younger than 50 years, 89 were between 50 and 59 years, 29 were between 60 and 64 years, 20 were between 65 and 69 years and seven older than 70 years. Stem cell source was BM in 212 (64%) and PBSC in 119 (36%) of the transplantations.
Thirty-three donors donated multiple times. Twelve donors donated BM twice, 15 donated PBSC twice, 4 donated BM and PBSC once each, one donor donated three times PBSC and one donor donated twice BM and twice PBSC each. Two recipients received BM from two different siblings. Two hundred seventy-seven (95%) donors were HLA-identical siblings and 14 (5%) were syngeneic twins (Table 1) .
Malignancies in donors
Sixteen (5%) of the 291 donors developed a total of 18 tumors of 10 different localizations (Table 2) : breast (4), prostate (3), skin (melanoma) (2), hematologic (ALL, CLL) (2), head/neck (2), lung (1), stomach (1), bladder (1), testis (1) and colon (1) . There were eight tumors in men and 10 in women. Two donors have developed two tumors (breast/ skin, lung/prostate, respectively). Fifteen donors were siblings, one a twin. Twelve donors had donated BM and four PBSC, including the one who donated PBSC three times. Their median age at donation was 42 years (range 25-66 years; median age 39.5 years for BM donors and 53.7 years for PBSC donors). Median age at diagnosis of the first tumor was 53.5 years (range 31-63 years, 55.5 years for BM donors and 52 years for PBSC donors), resulting in a median time interval from donation to diagnosis of a malignancy of 13 years in BM donors and 1.5 years in PB donors. One PBSC donor had already had a malignant tumor before donation but was considered to be cured at the time of 
Cumulative incidence of developing a malignancy at 20 years post-donation was 9.5%, which was similar to the one observed in recipients (8.7%, P ¼ 0.66; Figure 1) . However, more patients died during this period, resulting in a hazard ratio for developing a malignancy at 20 years postdonation for donors of 0.505 (95% confidence interval: 0.255-1.001, P ¼ 0.05) compared with recipients. Four donors (two men, two women) had died, three from cancer (acute lymphatic leukemia, breast cancer, stomach cancer, respectively) and one from cardiac disease. The age at death because of tumor complications was between 35 and 48 years, the donor who died from cardiac disease was 61 years old.
Comparison of the incidence of malignancies in donors and in general population
According to the Swiss Association of Cancer Registries incidence rate, 20.45 tumors would have been expected from these 291 donors during the observation time of 13 358 total observation years (RR: 0.88, P ¼ 0.7), 9.6 tumors in men and 11.9 in women. We observed 8 tumors in men (RR: 0.92) and 10 in women (RR: 0.84). In the age category of 0-49 years in men, 3 tumors were observed while 3.3 would have been expected (RR: 0.91). In the group of women of the same age category, 4 tumors were found while 6.8 (RR: 0.58) would have been expected. In the age category of 50-69 years, 5 tumors in men were observed while 4.5 would have been expected (RR: 1.11). In the group of women in the same age category, 6 tumors were observed while 4.8 would have been expected (RR: 1.23). None of these results demonstrated statistical significance. In the subgroup of men between 60 and 64 years, 1.07 tumors would have been expected while 4 were observed (RR: 3.7, Po0.02). No donor older than 70 years had developed a tumor yet. The distribution of the tumors' localizations was comparable to the distributions in general population.
Secondary malignancies in recipients
In 17 (6%) of the 289 recipients, a secondary tumor after transplantation was diagnosed during follow-up (Figure 1) . The localizations were skin (melanoma) (4), thyroid gland (2), head/neck (2), breast (1), cervix (1), ovary (1), colon (1), testis (1), nerves (1), bone (1), lung (1) and AML (1) . The mean time of diagnosis of secondary tumor post-transplantation was 11 years (range 1-26 years). Five of the recipients were dead at last follow-up.
Comparing the type of cancer in donor and recipient by pairs From the 16 donors with tumors, two donors developed a hematopoietic neoplasia. In one twin donor (UPN 161), ALL 
Discussion
This single center cohort study shows that a definite number of donors developed a malignancy after hematopoietic stem cell donation. The number of malignancies in donors was the same in absolute terms as in the recipients but significantly less in its cumulative incidence due to the higher non-tumor mortality in the recipients. Incidence of a malignancy in our donors was not different compared with the age-and sex-matched general population. Only in the small subgroup of men between 60 and 64 years were more malignancies observed than expected. However, the small number of donors and events in this subgroup does not allow one to draw any firm conclusions. The localizations of the tumors were consistent with those expected in the general population, that is breast, lung and skin. There were no differences between donors who donated BM or PBSC in this small data set. As such, these data are at least comforting. So far, few studies have been published concerning incidence of tumors in stem cell donors. The Spanish donor registry 15 found 5 cases (0.68%), occurring within 10 and 64 months after donation. These data were also consistent with the expected incidence compared with the general Spanish population. Most series including our own have the limitation that the number of siblings excluded from donation due to a prior malignancy is not known. Therefore, we cannot exclude that our donor population represents a positive selection of healthy siblings but it is unlikely that a potential bias would have been large enough to change conclusions.
The risk of developing a secondary malignancy is well known for recipients and a major concern in long-term survivors. 16, 17 As donors and recipients are HLA-identical siblings and there is a known association of the HLA system and cancer, we were also interested to compare type and localization of tumors in donors and recipients. Furthermore, siblings might share miscellaneous additional risk factors for developing malignancies. The number of malignancies in donors was similar to the number of secondary malignancies in their transplanted siblings and in general no relationship between the different localizations was observed. There were two exceptions with two donors who developed hematologic neoplasms, one of them the same as his twin. These findings fit the known familiar accumulation of hematopoietic malignancies.
Despite our negative findings, the potential influence of G-CSF remains a matter of debate. Bennett et al. 18 reported two cases of previously healthy persons, who received G-CSF and developed hematological malignancies. No causal relationship could be demonstrated. Anderlini et al. 10 published a review about biological and molecular effects of G-CSF in healthy individuals. Most changes on hematopoiesis seemed to be transient, but effects on immunity, inflammation and coagulation are not yet fully understood. Both donors suffering from a hematological tumor donated BM in our study, but numbers of donors included in our comprehensive retrospective cohort study are still small. Median latency between donation and diagnosis of a malignancy was shorter in donors for PBSC than BM. This might be explained by the differences in median age at first donation for donors diagnosed with malignancies (39.5 years for BM vs 53.5 years for PBSC donors) but strongly underlines the need for careful pretransplant donor evaluation.
In summary, tumors do occur in donors of hematopoietic stem cells in similar rates as expected in a general population. So far, no risk factors can be identified and an impact of growth factors cannot be excluded with certainty. These data underline the need for a concerted international long-term donor follow-up.
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